Clinical Trial Update: A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography) [Phase 1]

View source ↗

Summary

Phase 1 PET study evaluating kappa opioid receptor occupancy of PF-04455242 in bipolar disorder and depression has been terminated. Sponsored by Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Drugs mentioned

• PF-04455242 (PF-04455242)

Snippet

Sponsor: Pfizer | Conditions: Bipolar Disorder, Depression | Phase 1 | Status: TERMINATED